Free Trial

Oramed Pharmaceuticals (ORMP) Competitors

Oramed Pharmaceuticals logo
$2.27 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.25 -0.02 (-0.84%)
As of 04:07 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

ORMP vs. FDMT, ENGN, KMDA, YMAB, AMRN, TVRD, AURA, DRUG, REPL, and DMAC

Should you be buying Oramed Pharmaceuticals stock or one of its competitors? The main competitors of Oramed Pharmaceuticals include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Kamada (KMDA), Y-mAbs Therapeutics (YMAB), Amarin (AMRN), Tvardi Therapeutics (TVRD), Aura Biosciences (AURA), Bright Minds Biosciences (DRUG), Replimune Group (REPL), and DiaMedica Therapeutics (DMAC). These companies are all part of the "pharmaceutical products" industry.

Oramed Pharmaceuticals vs. Its Competitors

4D Molecular Therapeutics (NASDAQ:FDMT) and Oramed Pharmaceuticals (NASDAQ:ORMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

4D Molecular Therapeutics presently has a consensus target price of $30.40, indicating a potential upside of 201.29%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe 4D Molecular Therapeutics is more favorable than Oramed Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
4D Molecular Therapeutics
2 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.55
Oramed Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

4D Molecular Therapeutics has a beta of 2.93, suggesting that its share price is 193% more volatile than the S&P 500. Comparatively, Oramed Pharmaceuticals has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500.

In the previous week, 4D Molecular Therapeutics had 5 more articles in the media than Oramed Pharmaceuticals. MarketBeat recorded 6 mentions for 4D Molecular Therapeutics and 1 mentions for Oramed Pharmaceuticals. Oramed Pharmaceuticals' average media sentiment score of 0.83 beat 4D Molecular Therapeutics' score of 0.58 indicating that Oramed Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
4D Molecular Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oramed Pharmaceuticals
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Oramed Pharmaceuticals has higher revenue and earnings than 4D Molecular Therapeutics. Oramed Pharmaceuticals is trading at a lower price-to-earnings ratio than 4D Molecular Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D Molecular Therapeutics$40K11,780.08-$160.87M-$3.53-2.86
Oramed Pharmaceuticals$2M46.54-$19.06M-$0.35-6.49

Oramed Pharmaceuticals has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -594,375.81%. Oramed Pharmaceuticals' return on equity of -19.37% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
4D Molecular Therapeutics-594,375.81% -40.15% -36.43%
Oramed Pharmaceuticals N/A -19.37%-18.28%

99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 12.7% of Oramed Pharmaceuticals shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by company insiders. Comparatively, 17.8% of Oramed Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

4D Molecular Therapeutics and Oramed Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Oramed Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ORMP vs. The Competition

MetricOramed PharmaceuticalsMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$93.08M$10.61B$6.13B$10.46B
Dividend YieldN/A1.91%5.73%4.78%
P/E Ratio-6.4920.0185.1527.20
Price / Sales46.5426.48573.26177.33
Price / CashN/A25.0737.3961.86
Price / Book0.633.4212.396.65
Net Income-$19.06M$208.83M$3.32B$276.79M
7 Day Performance-4.22%-2.34%-0.24%-1.51%
1 Month Performance-0.87%1.21%9.56%5.45%
1 Year Performance-6.58%-7.89%71.66%36.24%

Oramed Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ORMP
Oramed Pharmaceuticals
0.5559 of 5 stars
$2.27
flat
N/A-3.4%$93.08M$2M-6.4910
FDMT
4D Molecular Therapeutics
3.012 of 5 stars
$8.40
-1.8%
$30.40
+261.9%
+12.0%$399.31M$40K-2.38120Gap Up
ENGN
enGene
3.3498 of 5 stars
$7.60
-1.9%
$19.50
+156.6%
+4.8%$396.74MN/A-4.0031Analyst Forecast
Gap Down
KMDA
Kamada
4.4778 of 5 stars
$6.70
-1.8%
$13.00
+94.0%
+25.2%$392.18M$160.95M19.71360Positive News
YMAB
Y-mAbs Therapeutics
1.1445 of 5 stars
$8.61
flat
$9.62
+11.8%
N/A$391.24M$87.68M-17.22150
AMRN
Amarin
0.6236 of 5 stars
$19.33
+2.6%
$12.00
-37.9%
+73.5%$389.66M$228.61M-5.27360News Coverage
High Trading Volume
TVRD
Tvardi Therapeutics
2.5344 of 5 stars
$40.18
-0.1%
$64.25
+59.9%
N/A$377.25M$7.14M0.0080Trending News
Analyst Downgrade
Analyst Revision
AURA
Aura Biosciences
1.8119 of 5 stars
$5.92
-2.1%
$22.00
+271.6%
-35.6%$375.83MN/A-3.0250
DRUG
Bright Minds Biosciences
2.9442 of 5 stars
$51.50
-3.3%
$81.00
+57.3%
+76.8%$375.16MN/A-55.38N/ANews Coverage
Positive News
Analyst Upgrade
REPL
Replimune Group
4.3555 of 5 stars
$4.68
-1.1%
$6.50
+38.9%
-55.0%$369.21MN/A-1.44210Positive News
Analyst Forecast
DMAC
DiaMedica Therapeutics
1.683 of 5 stars
$6.93
-2.0%
$12.33
+78.0%
+58.4%$365.44MN/A-10.0420

Related Companies and Tools


This page (NASDAQ:ORMP) was last updated on 10/16/2025 by MarketBeat.com Staff
From Our Partners